Antheia receives $40 million in venture debt financing



Antheiaa synthetic biology company, announced $40 million in venture debt financing from Oxford Finance LLC and Silicon Valley Bank, alongside plans to build a new pilot-scale biomanufacturing facility .

The funding will support Antheia’s expansion with a 14,700 square foot pilot plant located adjacent to Antheia’s headquarters in Menlo Park, California. The new pilot plant will allow the company to significantly improve its efficiency and support the scaling of its growing product portfolio.

“Pilot plants are a critical part of scaling biomanufacturing, and high-quality pilot plant capability is increasingly scarce in the United States,” said Zack McGahey, COO at Antheia. “As we advance our entire pipeline of drug candidates, investing in our own on-site facility will be key to optimizing strain performance and improving efficiency as we transition to industrial-scale production. “

The planned facility will provide Antheia with 500 liters of additional fermentation capacity to support the scale-up of various active pharmaceutical ingredients (APIs). By using this facility, the company expects to save two to four months of time per cycle, improve customer engagement through accelerated sample and validation times, and increase utilization rates. Antheia will begin construction in 2023 with the goal of being operational by the end of 2023.

“Antheia uses synthetic biology to create existing and new drugs in a more controlled and cost-effective way,” said Christopher A. Herr, senior managing director at Oxford Finance. “We are excited to partner with Silicon Valley Bank to support Antheia’s facility expansion and growing product portfolio.”

“We are thrilled to support Antheia and its mission to disrupt the traditional agricultural supply chain and accelerate the discovery of new medicines,” said Peter Sletteland, Director of Life Sciences and Healthcare at Silicon Valley. Bank. “As lenders focused on the long-term growth trajectory, we are excited about the future of the business.”

Antheia aims to transform the supply chain of plant-based APIs which are essential for the development of many essential medicines, but which depend on fragile, unpredictable, inefficient and expensive agricultural sources. Using synthetic biology, Antheia is developing several classes of plant-based APIs that cannot be made by synthetic chemistry, including painkillers, neurotransmitter inhibitors, sedatives, chemotherapeutic agents, and anti-infectives. This funding enables Antheia’s strategic investment in a pilot plant, which will be instrumental in optimizing the process of scaling up the company’s plant-based compound pipeline, which is aligned with the lists. essential medicines from the FDA and the WHO.

Besides announcing its new pilot plant, Antheia has also joined the Association for Accessible Medicines (AAM). AAM was founded to improve access to safe, high quality and effective medicines for all and is well aligned with Antheia’s mission to transform pharmaceutical supply chains to ensure equitable access to essential medicines.

Source link


About Author

Comments are closed.